Lv4
638 积分 2025-03-26 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
27天前
已完结
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
3个月前
已完结
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
3个月前
已完结
Intrapleural Therapy for Malignant Pleural Effusions
3个月前
已完结
Management of Malignant Pleural Effusion
3个月前
已完结
Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010
3个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
5个月前
已完结
Emerging importance of HER3 in tumorigenesis and cancer therapy
5个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
5个月前
已完结
The Current and Future Management of Malignant Ascites
6个月前
已完结
皖公网安备34019202002308
